For Eye Care Professionals
Dr. Yehia Hashad will Join Bausch + Lomb Corporation as Executive Vice President of Research & Development and Chief Medical Officer
New Survey from Bausch + Lomb and Glaucoma Research Foundation Reveals Emotional and Social Impact of Hyperemia on Glaucoma Patients
Bausch + Lomb Reports More Than 41 Million Units of Contact Lens, Eye and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs
Bausch + Lomb Will Present Scientific Data and Analyses during the American Academy of Ophthalmology and American Academy of Optometry Annual Meetings
Bausch + Lomb Launches Biotrue® Eye Care Recycling Program in Collaboration with TerraCycle in the United States
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial of NOV03 (Perfluorohexyloctane) in Dry Eye Disease Associated With Meibomian Gland Dysfunction
Bausch + Lomb Will Present 14 Scientific Posters Featuring New Analyses Involving its Surgical Technologies at the 2021 Annual Meeting of the American Society of Cataract and Refractive Surgery
Bausch + Lomb Launches Biotrue® Hydration Boost Lubricant Eye Drops and Biotrue® Micellar Eyelid Cleansing Wipes
Bausch + Lomb Completes Enrollment of Second Phase 3 Study for NOV03 (perfluorohexyloctane)
Bausch + Lomb Expands Parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses
Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software
Bausch + Lomb and Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE™ (Triamcinolone Acetonide Suprachoroidal Injectable Suspension)
Bausch + Lomb and Prevent Blindness Launch Educational Campaign During Cataract Awareness Month
New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues to Reduce the Risk of Moderate to Advanced Age-Related Macular Degeneration Progression
Bausch + Lomb Will Present New Scientific Data and Analyses on Products and Pipeline Programs During the Association for Research in Vision and Ophthalmology Meeting
Bausch + Lomb Announces Statistically Significant Topline Results from the First Phase 3 Trial of Nov03 (Perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction
FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device (OVD)